|
|
“Growing numbers
of specific and costly treatment options with relatively low response
rates have created a need for diagnostic tools that aid in correct therapeutic
selection and monitoring of treatment response”
– Genetic Engineering News |
 |
|
|
- Enlyton is presently validating a proprietary cancer-specific tracer for use in improving the cancer detection capability of Positron Emission Tomography (PET) / Computed Tomography (CT). Initial experimentation has demonstrated the advantages of ATA series antibody targets for use in PET/CT
- In parallel, Enlyton has conducted in vivo studies that demonstrate promise for the use of ATA antibodies in real time fluorescence detection of cancer intraoperatively
- Enlyton is characterizing and validating other molecular targets and techniques that address imaging and detection applications for adenocarcinoma and other cancers
|